New Delhi, May 16th, 2026: Mankind Pharma today launched “Act at 30 – It’s Time for a Heart Check,” a nationwide preventive health movement aimed at redefining when cardiovascular vigilance must begin, shifting the focus to age 30.
Emerging clinical evidence indicates that nearly one in four Indians aged 30–39 may already be hypertensive or pre-hypertensive, often without being aware of it until complications arise. Stress, rapid urbanisation, sedentary lifestyles, and genetic predisposition are accelerating the onset of cardiovascular risk, compressing what was once considered a middle-age condition into a much earlier phase of life.
A large-scale survey conducted by Mankind Pharma, capturing responses from over 20,000 healthcare professionals including general physicians, consulting physicians, and cardiologists across India, found that more than 90 percent of clinicians recommend initiating heart health screening from the age of 30. However, there is no widely adopted, standardised national protocol that clearly establishes age 30 as a preventive screening milestone.
“Act at 30” has been conceptualised to address this gap by encouraging individuals to undergo a baseline cardiovascular assessment at 30, enabling earlier detection and timely intervention. The initiative advocates a comprehensive first screening that includes evaluation of blood pressure, blood glucose, lipid levels, and obesity-related risk factors, helping identify early warning signs before they progress into serious conditions such as heart attacks, stroke, or kidney disease.
The scientific foundation of the initiative is reinforced by a peer-reviewed national paper published in The Journal of Clinical Hypertension, co-authored by leading cardiologists from across India, which supports the need to lower the screening threshold and prioritise early detection.
Since its rollout, the initiative has already demonstrated meaningful on-ground momentum. More than 100,000 individuals have been screened across parameters including blood pressure, ECG, and lipid profiles.
Commenting on the initiative, Sudipta Roy, Senior President – Sales and Marketing, Mankind Pharma Ltd, said:
“India’s cardiovascular risk is clearly shifting to younger age groups, but awareness and screening have not kept pace. Hypertension at 32 carries the same clinical consequences as at 52, yet it offers a far more meaningful window for early intervention and long-term risk reduction. The real challenge is that diagnosis is still happening too late. ‘Act at 30’ is about bringing that intervention point forward and making early screening a routine part of how individuals think about their health. In a context where nearly one in four adults in this age group may already be hypertensive without knowing it, early screening is no longer optional, it is essential.”
Going forward, the initiative will expand through community and workplace screening programmes, development of a national consensus framework in collaboration with leading medical experts and sustained public engagement across digital and on-ground platforms.
Mankind Pharma aims to establish age 30 as a widely recognised preventive health checkpoint in India, encouraging earlier diagnosis, improving long-term outcomes, and contributing to the country’s broader efforts to manage non-communicable diseases.
About Mankind Pharma
Mankind Pharma (BSE: 543904 | NSE: MANKIND) is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence. Mankind operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company is a leading player in the domestic pharmaceuticals business present across acute and chronic therapeutic areas including anti-infectives, cardiovascular, Gr Mankind/II- gastrointestinal, antidiabetic, neuro/CNS, gynecology, VMN and respiratory, among others with a strategy to increase chronic presence going ahead. In the consumer healthcare business, the company operates in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories, among others, with several category-leading brands. Following the acquisition of Bharat Serums and Vaccines Limited, Mankind Pharma has further strengthened its leadership in the domestic women’s health segment. Mankind’s distribution network includes a robust field force of 17,700+ professionals, and a reach extending to over five lakh doctors across urban and rural markets. The company has 32 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. Mankind has a consistent track record of product innovation through 6 dedicated R&D facilities backed by more than 730 scientists
